HARRISBURG, PA — A $7.4 billion national settlement with Purdue Pharma and the Sackler family is now in effect, paving the way for more than $200 million in funding to flow to Pennsylvania for opioid addiction treatment, prevention, and recovery efforts.
What This Means for You
- Funding for addiction treatment and recovery programs will expand statewide
- Payments will be distributed over 15 years, with most funds arriving early
- The Sackler family is permanently barred from selling opioids in the U.S.
Attorney General Dave Sunday said the agreement concludes years of litigation over Purdue Pharma’s role in the opioid crisis, which involved the widespread marketing of prescription painkillers that contributed to addiction and overdose deaths nationwide.
Pennsylvania is expected to receive more than $200 million over 15 years, with funds potentially reaching state and local governments as early as late 2026.
How the Settlement Works
The settlement resolves claims that Purdue Pharma and its owners, the Sackler family, helped drive the opioid crisis through aggressive marketing of opioid medications.
A multistate investigation began in 2016, and Pennsylvania filed its lawsuit in 2019.
After Purdue filed for bankruptcy later that year, state attorneys general played a central role in negotiating the final agreement, including securing additional payments after the U.S. Supreme Court rejected parts of an earlier settlement in June 2024.
“This $7.4 billion settlement is a major step in holding Purdue Pharma and the Sackler family accountable,” Sunday said.
Where the Money Goes
Settlement funds will be distributed to states, local governments, individuals, and other claimants affected by the crisis.
Most of the funding will be delivered in the first three years.
Payments include:
- More than $1.5 billion from the Sackler family immediately
- Additional payments scheduled through 2029
- Approximately $900 million from Purdue Pharma
Officials said the funds will support programs focused on addiction treatment, prevention, and recovery.
With this agreement, Pennsylvania has secured more than $2 billion in total opioid settlement funding.
Industry Changes and Oversight
As part of the settlement, Purdue’s operations will transfer to a new company, Knoa Pharma LLC, which will be overseen by an independent board with no prior ties to Purdue.
The agreement prohibits the company from marketing opioids and requires independent monitoring to reduce the risk of misuse or diversion — the illegal redirection of prescription drugs for nonmedical use.
The settlement also requires the release of more than 30 million documents related to Purdue’s opioid business.
Broad National Agreement
The settlement includes attorneys general from all eligible states and U.S. territories, resolving widespread litigation tied to the opioid crisis.
Officials said the agreement represents one of the largest legal resolutions connected to the crisis, which has affected communities across Pennsylvania and the country for decades.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.